Biosergen publishes 2023 annual report

Friday, May 10, 2024: Biosergen AB (“Biosergen” or the “Company”) publishes annual report for the financial year 2023. The annual report is now available on the company website ( www.biosergen.net )

To download the annual report, follow the link https://biosergen.net/investors/filings

For further information about Biosergen, please contact:

Tine Olesen, CEO
Telephone: +45 3135 5707
E-mail: tine.olesen@biosergen.net

Niels Laursen, CFO
Telephone: +45 4014 5059
E-mail: niels.laursen@biosergen.net

The Company’s Certified Adviser is Carnegie Investment Bank AB (publ).

ABOUT BIOSERGEN
Biosergen is a biotechnology company in the clinical stage within the therapeutic field of life-threatening fungal diseases. Biosergen’ s mission is to develop the drug candidate BSG005, into a new first line treatment choice for resistant and/or difficult to treat invasive fungal infections, to save thousands of lives of immune-compromised cancer- transplant- and AIDS patients every year.